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Abstract
Formation of resilient biofilms on medical devices colonized by pathogenic microorganisms is a major cause of health-care
associated infection. While in vitro biofilm analyses led to promising anti-biofilm approaches, little is known about their
translation to in vivo situations and on host contribution to the in vivo dynamics of infections on medical devices. Here we
have developed an in vivo model of long-term bacterial biofilm infections in a pediatric totally implantable venous access
port (TIVAP) surgically placed in adult rats. Using non-invasive and quantitative bioluminescence, we studied TIVAP
contamination by clinically relevant pathogens, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and
Staphylococcus epidermidis, and we demonstrated that TIVAP bacterial populations display typical biofilm phenotypes. In
our study, we showed that immunocompetent rats were able to control the colonization and clear the bloodstream
infection except for up to 30% that suffered systemic infection and death whereas none of the immunosuppressed rats
survived the infection. Besides, we mimicked some clinically relevant TIVAP associated complications such as port-pocket
infection and hematogenous route of colonization. Finally, by assessing an optimized antibiotic lock therapy, we established
that our in vivo model enables to assess innovative therapeutic strategies against bacterial biofilm infections.
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Introduction
Microbial contamination originating from patients and health-
care workers leads to formation of bacterial and fungal biofilms on
the surface of indwelling medical devices [1,2]. In addition to
mechanical hindrance, device-associated biofilms are a primary
cause of hospital-acquired (nosocomial) infections that are difficult
to eradicate due to the high tolerance of biofilms towards
antimicrobial and host defenses [3,4]. Currently, although biofilms
constitute a major threat to patients, there is no truly efficient
method for eliminating biofilms except the traumatic removal of
contaminated devices [5,6]. These invasive procedures often
involve difficult therapeutic decisions leading to increased cost of
additional treatments [7,8]. Hence, in light of this socio-economic
burden, there is a need for efficient prophylaxis against pathogenic
biofilm developing on implanted medical devices.
A number of anti-biofilm strategies have recently emerged from
in vitro studies of the biofilm physiology of model bacteria
[9,10,11,12]. Moreover several animal models using subcutane-
ously implanted or vascular catheters were successfully used to
evaluate the antimicrobial efficacy of several antibiotics against
bacteria such as Staphylococcus aureus and Staphylococcus epidermidis,
and to assess the role of regulators or virulence factors in biofilm
development [9,13,14,15,16,17,18,19]. However, these approach-
es were mainly designed to study short-term biofilm infections, and
rarely integrated both microbial and host contribution into
development of biofilm infections.
Repeated access to totally implantable venous access ports
(TIVAP) often leads to formation of intraluminal biofilms which
constitute reservoirs of local and systemic infections in human
patients [20]. In order to study catheter-related biofilm infections,
we developed an in vivo model of long-term biofilm infection using
pediatric TIVAP surgically implanted in adult rats. We used
immunocompetent and immunosuppressed rats to monitor
TIVAP contamination by clinically relevant bioluminescent
pathogens, including Escherichia coli, Pseudomonas aeruginosa, S. aureus
and S. epidermidis. We show that i) the bacterial population
colonizing TIVAP display all classical biofilm phenotypes and ii)
that the immunological status of implanted rats determine the
onset of bloodstream infection and organ colonization upon
release of bacteria from TIVAP biofilms. Finally, we show that our
model reproduces most clinically relevant situations associated
with TIVAP-related infections and we demonstrate its potential in
evaluating the efficiency of biofilm antibiotic lock eradication
strategies.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37281This model contributes to a better understanding of device-
related infections and constitutes a relevant approach for
validating diagnostic and therapeutic anti-biofilm approaches.
Materials and Methods
Microbiological evaluation of extracted TIVAP
Microbiological analysis procedure. TIVAP catheter tip
culture was performed on blood agar by a quantitative method
with a 10
3 colony-forming unit (CFU)/mL threshold, as described
[6,21]. Species identification of Enterobacteriaceae, coagulase-nega-
tive staphylococci and yeasts relied on use of APIH 20E, APIH
Staph and APIH 20C AUX test kits (BioMe ´rieux, Marcy l’Etoile,
France), respectively. Those data were generated as part of routine
activities in the clinical microbiology laboratory of the Institut
Curie hospital. Between 2007 and 2010, 600 TIVAP were
removed for suspicion of infection and 279 cultures (46.5%) were
positive with at least one microorganism. Those TIVAP originated
mostly from adult patients (219/279, 78%) with a median age of
43 [0–83] years. Finally, 292 microorganisms were responsible for
those 279 TIVAP-related infections (Table S1).
Bacterial strains
Luminescent variants of four clinically relevant pathogens, i.e.
E. coli, P. aeruginosa, S. aureus and S. epidermidis were purchased (S.
aureus Xen36 and S. epidermidis Xen43 from Caliper) or gifted (P.
aeruginosa Lm1, a bioluminescent derivative of the PAK clinical
strain [22] and E. coli EAEC 55989 [23] transformed with stable
plasmid pAT881 [24]). E. coli and P. aeruginosa strains were grown
in lysogeny broth (LB); S. aureus Xen36 and S. epidermidis Xen43
were cultured in tryptic soy broth (TSB) supplemented with 0.2%
glucose at 37uC.
In vitro biofilm formation
All experiments were carried out at least in triplicate. Catheter-
associated biofilms were developed in the lumen of pediatric
TIVAP (cat # 2105ISP, Polysite Micro, Titanium 2000 series,
Perouse Medical, France) composed of a titanium microport with
an 8 mm silicone septum and a radio-opaque catheter with
0.65 mm internal diameter. A Huber needle was inserted into the
silicone septum of the port for continuously supplying fresh
medium from reservoir bottles (Figure 1). The system is set up in
laminar airflow to maintain sterility. A bacterial dose of 100 cells/
100 mL was optimal to form intraluminal biofilms in TIVAP in
vitro. Bacterial inoculum of 100 cells/100 mL was injected through
the septum of the port and allowed to adhere to the TIVAP
surface for 3 h at 37uC before continuous flow was turned on at a
speed of 300 mL/min for 24 h. The spent media and non-
adherent cells were collected in a waste container. Control
catheters were prepared without bacterial inoculation. TIVAP
were disconnected under sterile conditions and monitored for
bioluminescence using an IVIS-100 imaging system with a charge-
coupled device (CCD) camera (Xenogen Corporation, Alameda,
CA, USA). The CFU/mL and bioluminescent signal (ROI, p/S/
cm
2/sr) correlation was determined by separately comparing
viable cell counts obtained for catheter and port.
Extraction and quantification of biofilm bacteria
TIVAP were carefully wiped with 70% EtOH before extracting
intraluminal biofilm bacteria to avoid contaminant. The catheter
was cut into small pieces and a slit was made horizontally to
expose the lumen and transferred to a tube containing 1 ml sterile
1X phosphate-buffered saline (PBS). The septum was removed
from the port using a sterile scalpel and forceps, cut into small
pieces and transferred to a separate tube containing 1 mL sterile
1X PBS. Cells attached to the titanium body of the port were
scratched in 100 mL 1X PBS and transferred to the same tube as
the septum. Biofilm that formed on the septum and in the lumen
of catheter was extracted by vigorously vortexing the tubes for
1 min, followed by transferring them to an ultrasonic water bath
(NEYtech Ultrasonik, 44–48 Khz) for 5 min. The bacterial
suspension was then diluted serially, plated on agar plates and
incubated at 37uC for colony counts. CFU/mL and biolumines-
cent signals (ROI, p/S/cm
2/sr) were plotted together for
correlation.
Animal model
Catheter placement. CD/SD (IGS:Crl) male rats (Charles
River) weighed 275–300 g and were acclimatized to a 12 h day/
night cycle for one week prior to use. Animals were anesthetized
using a 500 mL cocktail (7:2:1, v/v) of ketamine (Imalgen 1000,
Merial SAS Lyon, FR), xylazine (Rompun 2%, Bayer Healthcare,
Germany) and acepromazine (Calmivet Solution Injectable,
Vetoquinol SA, Lure, FR) given intraperitoneally. Rats were
shaved prior to placement of TIVAP and their skin was cleaned
using 70% alcohol and 10% povidone-iodine solution.
Surgical placement of TIVAP. The port was implanted at
dorsal midline towards the lower end of the thoracic vertebrae by
creating a subcutaneous pocket. The port was held in place using
sutures. 10/11 cm catheter was tunneled subcutaneously using a
tunneling rod onto the ventral side in the clavicle region, cut open
by an incision to expose the right external jugular vein for catheter
insertion. The catheter was inserted into the jugular vein by
making a micro-incision and progressively moved into the superior
vena cava up to the right atrium. The catheter was held in place
by ligating proximally and distally with sterile surgical silk thread
(Ethicon, 3-0). Functionality of TIVAP was maintained by flushing
1X sterile PBS followed by a heparin lock (500 IU/mL) every day.
Prior to inoculation of clinical strains, all rats were checked for the
absence of infection by plating 100 mL blood as well as monitoring
rats for the absence of luminescence signals.
TIVAP contamination in immunocompetent rats. The
inoculum dose was optimized by injecting within TIVAP
increasing doses of each bacteria and then selecting the smaller
inoculum giving an observable bioluminescent signal as compared
to TIVAP injected with PBS 1X. The inoculum dose was
optimized to 10
4 cells for E. coli,1 0
6 cells for P. aeruginosa and S.
aureus. For S. epidermidis the maximum dose that could be used was
10
8 cells but did not lead to bioluminescent-detectable coloniza-
tion (see Results). Overnight grown cultures were diluted in 1X
PBS to the optimized inoculum dose. The inoculum dose was also
confirmed by plating it for CFU/mL on respective antibiotic-
containing plates. Briefly, 100 mL 1X PBS containing the
optimized inoculum cell size was injected through a silicone
septum into the port using a Huber needle (total TIVAP dead
volume 250 mL). Control rats received 1X PBS. Progression of
colonization from the port to the distal end of the catheter was
monitored using an IVIS100 imaging system.
Immunosuppression and infection in catheterized rats
Rats were injected intraperitoneally with cyclophosphamide
(Sigma Aldrich cat# C0768-5G). Dose and regimen of cyclo-
phosphamide delivery were optimized by estimating blood total
leukocyte count as determined using an animal blood cell counter
(Vet abc, SCIL, Germany). Furthermore, the physical state of rats
such as lack of appetite, reduced weight and loss of hair indicated
immunosuppressed status. One hundred mg/kg body weight of
cyclophosphamide was finally selected for giving intraperitoneal
A New In Vivo Model of Biofilm Infection
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50 mg/kg on day -1 of inoculation. An optimized inoculum dose
of 10
2 cells/100 mL 1X PBS for all bacterial strains (higher
inoculum doses lead to the death of animals overnight) was used
for TIVAP contamination and was confirmed by plating for CFU/
mL. Control catheterized and immunosuppressed rats received
100 mL 1X PBS only. Prior to inoculation of clinical strains, all
rats were checked for the absence of infections as for immuno-
competent rats.
Peripheral blood and organ sampling
Blood was aseptically sampled (at day 4 and day 8 for
immunocompetent rats and day 3 for immunosuppressed rats)
by puncturing the retro-orbital sinus plexus of anesthetized rats
with a Pasteur pipette. One hundred and fifty microliters of blood
was transferred to a tube containing 10 mL of 100 IU/mL heparin
(day 4 and day 8) whereas another 50 mL was transferred to an
eppendorf tube containing 50 mL 0.01 M EDTA stored on ice
until analyzed (day 4 post infection). Blood with heparin was
serially diluted and plated on antibiotic plates for CFU/mL
estimation. Blood in EDTA was used for TLC (total leukocyte
count) and DLC (differential leukocyte count) using automated
blood cell analyzer (ABC vet 2.0, Germany) post day 4 of
infection. Metastatic infection resulting from TIVAP-associated
biofilm was determined by aseptically harvesting organs (heart,
lungs, liver and kidneys) on the final day of the experiment.
Organs were weighed and homogenized in 5 mL 1X sterile PBS
and serial dilutions were plated for estimating the CFU/organ.
Electron microscopy
After aseptic removal of colonized TIVAP from rats, 1 cm
catheter of the catheter tip was cut and the septum was dissected
from the port using a scalpel. Septum and catheter pieces were
washed twice in cacodylate solution (0.07 M) and then fixed in EM
fixative solution. Samples were stored at 4uC until sent for
microscopy (not more than 10 days).
Figure 1. Monitoring of in vitro biofilm-forming capacity of clinically relevant strains. (A) in vitro continuous flow system to grow biofilms
inside TIVAP. After 24 h biofilm formation in TIVAP was confirmed by scanning electron microscopy (SEM) for the four bacteria (B) and
bioluminescence activity was acquired using an IVIS 100 camera (C). (D) Biofilm was analyzed by plating CFU/mL (n=3 for each bacteria) on LB agar
(E.c., E. coli or P.a., P. aeruginosa) or TSB agar (S.a., S. aureus or S.e., S. epidermidis) plates. Relative luminescence was correlated with CFU/mL by
quantitative analysis of luminescence signals in the port and catheters separately using Living Image software.
doi:10.1371/journal.pone.0037281.g001
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S. aureus Xen36 was used to check the possibility of TIVAP
colonization through the venous system. An inoculum of 5610
8
cells of S. aureus Xen36 was centrifuged, washed and resuspended
in 500 mL 1X PBS. Bacteria were injected into the bloodstream
through the lateral tail vein. Animals were monitored for
luminescence using the IVIS-100 imaging system for infection
and colonization. The animals were sacrificed on day 3 after
injection and TIVAP were removed to confirm colonization by
luminescence and plating CFU/mL.
In vivo antibiotic lock technique (ALT/antibiotic lock
therapy)
Antibiotics and their concentration for ALT studies were chosen
based on recommendations made by IDSA guidelines [6].
Vancomycin, cefazolin and gentamicin were obtained from Sigma
Aldrich. The minimum inhibitory concentration (MIC) of all drugs
used in the study was determined by the macrodilution method in
Eppendorf tubes against all bacterial strains used in the study.
Cefazolin, Gentamicin and Vancomycin MICs of S. aureus Xen36
were 0.625, 0.3125 and 1 mg/mL respectively. Efficacy of
cefazolin ALT (5,000 mg/mL, 5000 IU/mL heparin) and genta-
micin ALT (1,000 mg/mL, 2,500 IU/mL heparin) was evaluated
against S. aureus Xen36. The 4-day-old biofilm formed inside the
implanted TIVAP was locked (200 mL) with the above-discussed
antibiotics and monitored for biofilm clearance by measuring
luminescence. The lock was replaced every 24 h and the ALT
regimen (n=4 rats for each treatment) was followed for 5 days
along with daily subcutaneous injection of vancomycin (50 mg/
Kg), except for the first set of experiments where a significant
mortality (,30%, n=3/9) occurred following ALT regimen
without systemic treatment. Therefore, it was necessary to treat
the animal with systemic vancomycin during the course of ALT
treament. Rats were sacrificed after day 5 for estimating viable cell
count. For evaluating the efficacy of the complex ALT solution
against S. aureus Xen36 biofilm, highly concentrated doses of
gentamicin and cefazolin were mixed in a final 1:1 (v/v) ratio and
used to lock colonized TIVAP. Untreated and colonized
implanted TIVAP were used as controls.
Ethics Statement
Clinical sampling. Extracted TIVAP are considered medi-
cal wastes by the Integrated Clinical Research Center of the
Institut Pasteur. The project consisting of analysis of the bacterial
flora of TIVAP was registered under the number 2009-44 and
considered as a sensu stricto microbiological research project by the
Integrated Clinical Research Center of the Institut Pasteur
(December 02, 2009). Clinical specimens were gathered and
analyzed at the Institut Curie Hospital, Paris, France, a hospital
dedicated to cancer diagnosis and treatment and data were
analyzed anonymously.
Animal studies. Animals were housed in the Institut Pasteur
animal facilities accredited by the French Ministry of Agriculture
for performing experiments on live rodents (accreditation #A75-
15 27, issued on November 12, 2004; and #A75-15 04, issued on
May 22, 2008) in compliance with French and European
regulations on care and protection of laboratory animals (EC
Directive 86/609, French Law 2001-486, June 6, 2001). Protocols
were approved by the veterinary staff of the Institut Pasteur animal
facilities and were performed in compliance with NIH Animal
Welfare Insurance #A5476-01 issued on July 02, 2007.
Statistical analysis
Results for colony forming units and relative luminescence
(ROI, p/S/cm
2/sr) are mean +/2 standard deviation. Box-and-
whisker plot was used to display the degree of dispersion in data in
case of in vivo studies and show the median (horizontal bar) and
25th/75th percentile. Statistical differences were evaluated using
one-way ANOVA (Tukey multiple comparison test) included in
Graphpad Prism Version 5.0c. Different treatment groups were
considered statistically different if p values were lower than 0.05.
Results
Clinically relevant bioluminescent pathogens form in
vitro biofilms in TIVAP
To develop a relevant model of biofilm infection, we first
determined which bacterial pathogens most frequently contami-
nate human TIVAP in catheterized patients. For this, we
performed microbiological evaluation of TIVAP removed for
suspicion of infection in patients hospitalized at the Institut Curie
Hospital, Paris, France [6,21]. A total of 292 microorganisms were
responsible for 279 TIVAP-associated infections. 66.4% of TIVAP
were colonized by Staphylococcus spp. (31.1% by S. aureus and 18.5%
by S. epidermidis), 16.4% by Enterobacteriaceae (including 5.8% by E.
coli) and 12.3% by Pseudomonads (including 9.2% by P. aeruginosa)
(Table S1). Based on these data, we obtained or constructed
luminescent variants of clinical strains of E. coli (E. coli 55989
pAT881), P. aeruginosa (P. aeruginosa Lm1), S. aureus (S. aureus Xen36)
and S. epidermidis (S. epidermidis Xen43) and showed that, except for
weaker signals emitted by S. epidermidis Xen43, all other bacteria
produced bioluminescent signals (ROI, p/S/cm
2/sr) proportional
to colony-forming units (CFU) (Figure S1).
We then evaluated the capacity of chosen luminescent bacteria
to form in vitro biofilms in pediatric TIVAP using in vitro continuous
flow system (Figure 1A). In these conditions, E. coli, P. aeruginosa S.
aureus and S. epidermidis developed characteristic high-cell-density
biofilm structures (Figure 1B), which correlated with high CFU
counts and an increased luminescent signal (Figure 1CD).
These results therefore indicated that the four selected
luminescent strains might be used to monitor bacterial coloniza-
tion and biofilm formation in TIVAP.
Non-invasive monitoring of long-term bacterial infection
in rat-implanted TIVAP
To study medical device colonization in an in vivo context, we
implanted TIVAP in rats (Figure S2). After 4 days of recovery, we
checked for TIVAP sterility and functional connection with the rat
venous system before investigating TIVAP bacterial colonization
by E. coli 55989 pAT881, P. aeruginosa Lm1 S. aureus Xen36 and S.
epidermidis Xen43 luminescent bacteria. We then injected 100 mL
of bacterial inocula directly into the TIVAP port through
externally decontaminated skin using a Huber needle. This
inoculation volume was smaller than the TIVAP dead volume
(250 mL), therefore avoiding injection into the bloodstream. We
then monitored development and progression of TIVAP coloni-
zation as a function of luminescent signals.
As described in Material and Methods section, we determined
that injection of at least 10
4 E. coli (n=5), 10
6 P. aeruginosa (n=7)
and 10
6 S. aureus (n=6) cells led to a clear luminescence signal,
which progressed to the distal end of the catheter and peaked
within 48–96 h before receding to the TIVAP (Figure 2A–C). In
contrast, we could not identify a S. epidermidis (n=5) injection titer
leading to any detectable bioluminescence signals (data not
shown). Finally, whereas most of our experiments were interrupted
after 10 days post-inoculation (dpi), the bacterial luminescent
A New In Vivo Model of Biofilm Infection
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coli (n=2) and P. aeruginosa (n=2) could be detected up to a
minimum of 60 dpi (Figure S3), thereby demonstrating establish-
ment of long-term chronic colonization of TIVAP surgically
implanted in rats.
Bacterial colonization of rat-implanted TIVAP leads to
formation of characteristic biofilms
High bioluminescence signals were correlated to high bacterial
titers within TIVAP. Counts of viable bacteria in the TIVAP after
10 dpi indicated ,7.6 to 8.3-log CFU/mL (port) and ,7.5 to 9.2-
log CFU/mL (catheter) (Figure 3A) but a different co-relation
between ROI and CFU/mL from port was obtained for each
pathogen (Table S2). Moreover, electron microscopy (EM) showed
that TIVAP colonized by E. coli, P. aeruginosa and S. aureus
displayed characteristic bacterial biofilm structures (Figure 3B–D).
In contrast with in vitro biofilms, bacteria were often embedded in a
meshwork of host-derived fibrin-like material and associated with
host cells potentially corresponding to host immune cells (see for
example, Figure 3C–D–E). Interestingly, similar analyses per-
formed on 10 dpi TIVAP inoculated with a high inoculum of 10
8
S. epidermidis cells revealed clear biofilm formation (Figure 3E), but
without an increase in CFU counts, suggesting that the absence of
an in vivo S. epidermidis luminescent signal was not due to a lack of
colonization ability by S. epidermidis Xen43 (Figure 3A).
Clinical complications associated with use of TIVAP in
rats
To investigate whether TIVAP biofilms release bacteria, we
monitored the presence of bacteria in the bloodstream in rats
carrying colonized TIVAP. Peripheral blood was withdrawn from
the retro-orbital sinuses of rats with inoculated TIVAP on days 4
and 8 post-inoculation and plated on either LB agar (for rats
inoculated with E. coli and P. aeruginosa) or TSB agar plates (S.
Figure 2. Monitoring of TIVAP colonization by E. coli, P. aeruginosa and S. aureus. The port was implanted subcutaneously at the dorsal
midline and the catheter was inserted into the external jugular vein. Optimized doses of 10
4 CFU (E. coli,n=5 )o r1 0
6 CFU (P. aeruginosa, n=7 and S.
aureus, n=6) in 100 mL were injected into the port and photon emission measured over a period of 10 days to monitor biofilm growth. Dorsal and
ventral views of rats, showing progression of biofilm signals towards the catheter tip. Biofilm-associated infection was restricted to TIVAP by day 10.
Control rat was catheterized but without bacterial inoculation. A representative animal is shown.
doi:10.1371/journal.pone.0037281.g002
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the port and catheter after 48 h (cf. Figure 2), most rats, except for
those colonized by S. epidermidis, showed varying numbers of CFU
on day 4, thus indicating bacterial dissemination in bloodstream
(Figure 4A). In several cases, implanted rats colonized with S.
aureus (n=5/14, ,36%), P. aeruginosa (n=6/18, ,33%) and E. coli
(n=1/10, 10%) developed systemic infection leading to death
between day 8 and 10, associated with massive organ bacterial
colonization (Figure 4B).
At day 8, however, blood of all surviving TIVAP-infected rats
was sterile; analysis of bioluminescence signals and CFU counts in
Figure 3. Bacterial colonization of TIVAP leads to biofilm
formation. Rats were sacrificed 10 days post infection, TIVAP were
removed aseptically and cells harvested from the catheter and port
separately and plated on LB agar (E.c., E. coli n=5 or P.a., P. aeruginosa
n=7) or TSB agar (S.a., S. aureus n=6 or S.e., S. epidermidis n=5) plates
for CFU/mL (A). (B–E) SEM images confirming true biofilm formation in
TIVAP in vivo in the port and catheter. Representative images are
presented. White arrows indicate eukaryotic immune cells.
doi:10.1371/journal.pone.0037281.g003
Figure 4. Clinically relevant complications associated with
TIVAP biofilms. (A) Peripheral blood was harvested on day 4 (D4) and
day 8 (D8) post-inoculation and plated on LB agar (E.c., E. coli n=10 or
P.a., P. aeruginosa n=18) or TSB agar (S.a., S. aureus n=14 or S.e., S.
epidermidis n=5) plates for CFU/mL. Bacteria were cleared by day 8 in
most rats except for a few that suffered from systemic infection and
died. Each dot represents one animal and cross ({) signifies the dead
animal. (B) Organs were aseptically removed after sacrificing animals on
day 10. Graph includes only rats that suffered from systemic infection
and died. No bacteria were detected in the case of S. epidermidis (S. e.,
n=5), whereas 10% rats suffered from systemic infection and died due
to E. coli (E. c., n=1/10) or ,30% due to P. aeruginosa (P. a., n=6/18)
and S. aureus (S. a., n=5/14) biofilms associated with TIVAP. Data are
presented as box-and-whisker plots as previously described in material
and methods.
doi:10.1371/journal.pone.0037281.g004
A New In Vivo Model of Biofilm Infection
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37281lungs, heart, kidneys and liver aseptically removed from these rats
was consistently negative, even after 60 dpi, with colonization
restricted to the device (Figure 4A–B and S3). These results
indicated that our model mimicked chronic colonization of
implanted devices, with occasional catheter-related systemic
bloodstream infections.
In clinical situations, repeated intradermal needle puncture
during access to TIVAP is also associated with subcutaneous
bacterial infection around the port area [25]. Consistently, we
found that 20% of TIVAP-implanted rats inoculated with P.
aeruginosa or S. aureus (but not with E. coli) developed subcutaneous
port pocket infection. In addition to iatrogenic TIVAP-related
infections, bacteria from the patient bloodstream also constitute a
source of central venous catheter colonization. To test whether
TIVAP implanted in rats can also be colonized via a hematog-
enous route of infection, we injected 5610
8 luminescent S. aureus
bacteria through the lateral tail vein of TIVAP-implanted rats.
Although no signs of systemic infection were observed in rats 3
days post-injection, 30% (n=2/6) displayed a bioluminescent
signal and bacterial colonization at the catheter tip of the TIVAP
(Figure S4).
These results demonstrated that TIVAP implanted rats
experienced clinical situations such as biofilm-related bloodstream
infections, organs metastasis and port-pocket infections.
Role of the rat immune system in control of TIVAP biofilm
infections
Confinement of high cell density biofilms to the TIVAP and
clearance of bloodstream bacteria several days after inoculation
suggested active in vivo control of device-related infections. To test
the role of the rat immune system in this control, we transiently
immunosuppressed implanted rats prior to inoculation using
cyclophosphamide, a commonly used anti-cancer drug that causes
neutropenia and lowers the number of other white blood cells
[26]. Consistently, implanted cyclophosphamide-treated rats
displayed a 70% decrease in total blood leukocytes.
We observed that inoculation of TIVAP in immunosuppressed
rats with as low as 10
2 cells (in contrast to 10
4 to 10
8 in
immunocompetent rats) led to a strong luminescent signal in
inoculated TIVAP at day 1 post-inoculation, except for S.
epidermidis, which could not be monitored by luminescence
(Figure 5A). Strikingly, viable bacteria counts and electron
microscopy analyses revealed strong biofilm development for all
four bacteria tested in TIVAP aseptically removed from immu-
nosuppressed rats, with approximately ,9-log CFU/mL recov-
ered from ports or catheters (Figure S5). EM analyses also showed
that substantially fewer immune cells could be found in E. coli, P.
aeruginosa, S. aureus and S. epidermidis biofilms formed in TIVAP
ports and catheters of immunosuppressed rats compared to biofilm
formed in TIVAP implanted in immunocompetent rats
(Figure 5B).
In addition, whereas control (non-infected) immunosuppressed
rats survived, all inoculated rats ultimately died of massive acute
systemic infection between days 3 and 5, with bioluminescent
signals progressing from the TIVAP throughout the body for E.
coli, P. aeruginosa and S. aureus (Figure 5A). Collection of peripheral
blood on the day of the animals’ death showed that cyclophos-
phamide-treated rats were indeed bacteremic (Figure S5). Meta-
static infectious disease was confirmed by detection of strong
bioluminescence signals and a high CFU count in aseptically
removed organs (lungs, heart, kidneys, liver) (Figure S5).
These results showed that immunosuppressed rats were unable
to restrict the extent and outcome of TIVAP-related infections.
Interestingly, ,30% of immunocompetent rats that spontaneously
developed fatal systemic P. aeruginosa and S. aureus infection (see
above and Figure 4) showed an exacerbated inflammatory
response, as indicated by a significant increase in total white
blood cells and granulocytes in peripheral blood compared to
immunocompetent rats that controlled their TIVAP infection
(Figure S6).
Taken together, these results demonstrated that our model
enabled studying the role of the rat immune system in
development of acute biofilm-mediated systemic infection caused
by bacterial pathogens.
Evaluation of the anti-biofilm antibiotic lock in TIVAP
To evaluate the clinical relevance of our in vivo model, we chose
a widely used anti-biofilm method called the antibiotic lock
therapy (ALT) using cefazolin and gentamicin in TIVAP
inoculated with S. aureus Xen36. ALT corresponds to instillation
of a high concentration of antibiotics into the lumen of the catheter
for a dwelling time varying between 12 and 24 h [27]. In clinical
situations, ALT is associated with systemic antibiotic treatment to
prevent bloodstream infection originating from the TIVAP. We
observed that, while systemic vancomycin treatment avoided
bloodstream infections, ALT solutions composed of cefazolin or
gentamicin alone, mixed with heparin and used for 5 consecutive
days with daily replacement, did not completely eradicate S. aureus
biofilms in TIVAP, as indicated by the persistence of a
luminescence signal and the presence of 10
7–10
8 CFU/ml in
removed TIVAP (Figure 6). In contrast, use of the antibiotic lock
solution consisting of a combination of cefazolin and gentamicin
(1:1 V/V in heparin 2500 IU/mL) very effectively eradicated
TIVAP-associated biofilm (Figure 6). Interestingly, when ALT was
applied without systemic treatment, approximately 30% of
immunocompetent rats were unable to clear bloodstream infection
originating from TIVAP-associated biofilm bacteria flushed during
the ALT procedure, and rapidly died after instilling ALT,
therefore pointing to the risk of use of ALT treatment without
an associated systemic antibiotic treatment (Figure S7).
These results demonstrated that our in vivo model of biofilm
infection constitutes a relevant tool for evaluating the efficiency of
ALT protocols and investigating other clinical issues associated
with use of central venous catheters.
Discussion
We developed a novel in vivo model of bacterial colonization in
TIVAP and demonstrated that it constitutes a clinically relevant
tool for studying both microbial and host contribution to catheter-
related biofilm infections. TIVAP, developed in 1982 to replace
external catheters for antineoplastic chemotherapy, are commonly
used medical devices that are surgically implanted at chest level;
they are routinely employed to facilitate long-term repetitive
intravenous therapy [28]. Despite significant progress in clinical
handling of these catheters, biofilm development resulting from
external (skin and environment) or endogenous (bloodstream
infection) contamination remains a poorly understood process with
severe clinical ramifications [6,29]. The pediatric-sized TIVAP
used in our study are well adapted to small laboratory mammals;
their subcutaneous implantation prevents rapid accidental removal
by implanted animals, which obviates the need for cumbersome
restrainer jackets and enables long-term studies [18,30,31]. Unlike
other venous catheters, TIVAP are closed devices, thereby
considerably reducing the risk of unplanned contamination and
making them particularly amenable to controlled reproducible
long-term animal infection studies. We followed bacterial coloni-
zation using bioluminescence, a well-established technology for
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Here we show that, in addition to CFU count and electron
microscopy, bioluminescence can also accurately reflect the level
of bacterial colonization of the port, catheter and organs. Both the
literature and our own microbiological analysis of infected clinical
TIVAP showed that staphylococci account for more than 60% of
all identified pathogens in central venous-catheter-related infec-
tions [33]. While luminescent S. aureus could be used for
quantitative in vitro and in vivo monitoring of bacterial colonization
in TIVAP, the level of signals emitted by the only currently
available bioluminescent strain of S. epidermidis was insufficient to
permit its in vivo monitoring in TIVAP. Nevertheless, since S.
epidermidis is one of the leading causes of central-venous-catheter-
associated biofilm infections in a hospital environment, especially
in critically ill patients [34], we also used non-luminescent-based
approaches including microscopy and CFU count; we showed that
Figure 5. Immunosuppression led to fatal biofilm infection. (A) 10
2 CFU in 100 mL of the different bacteria were injected into the port of
TIVAP implanted in cyclophosphamide-treated rats (100 mg/kg day -4 and 50 mg/kg day -1 of inoculation) and photon emission was monitored up
to the death of the animals on days 3/5 to evaluate biofilm formation and associated infection. TIVAP were aseptically removed from dead animals
and photon emission measured for both the animal and the extracted TIVAP. Control rat was a catheterized and cyclophosphamide-treated but
without bacterial inoculation. (B) SEM images of TIVAP (port and catheter) infected with 4 clinical strains used in this study. Number of rats (n) used in
the experiment, n=4 for each strain.
doi:10.1371/journal.pone.0037281.g005
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We also demonstrated the capacity of E. coli and P. aeruginosa
pathogenic strains to colonize TIVAP. These Gram-negative
bacteria are often overlooked in studies using catheter-related
infection models, but recent data raise concern about their
increased importance in the microbiological epidemiology of
oncology patients, in addition to multiresistance associated with
those pathogens [35,36,37,38,39].
We demonstrated that in vitro and in vivo colonization of TIVAP
by the four tested bacteria led to formation of biofilms displaying
characteristic high cell density as shown by scanning electron
microscopy of both TIVAP septa and catheters, along with CFU
count. In clinical settings, the formation of pathogenic biofilms in
central venous catheters is responsible for bloodstream infections.
We reproducibly observed that controlled inoculation of implant-
ed TIVAP enabled biofilm development that occasionally led to
lethal systemic infections. In most cases, however, bacteria released
from persistent TIVAP biofilms were rapidly cleared from the
peripheral blood and organs of immunocompetent rats. This
situation could be maintained for up to 120 days, therefore
reproducing the presence of chronic biofilms in medical devices,
which are considered important potential infection reservoirs [25].
The persistence of biofilms in these devices for such a long
period of time clearly pointed to the incapacity of the host immune
system to clear such structured bacterial communities despite the
presence of immune cells in the observed biofilms. However,
colonization of TIVAP implanted in immunosuppressed rats by E.
coli, P. aeruginosa, S. aureus or S. epidermidis bacteria consistently led
to rapid acute systemic infection and death, therefore illustrating
the importance of host immune response in controlling bacterial
metastasis originating from persistent biofilms in colonized
TIVAP. Even in the case of poorly luminescent S. epidermidis,i n
accordance with a previous study using subcutaneously implanted
catheter segments [14], we showed that S. epidermidis biofilm-
associated infection was very efficiently cleared by the rat immune
system [34]. Our results are therefore consistent with clinical and
experimental evidence in support of a key contribution of host
immune system factors to the outcome of catheter-related
infections [40].
Besides mimicking of chronic and acute biofilm infections, rats
implanted with pediatric TIVAP also developed common clinical
complications such as port pocket infection and catheter tip
colonization via a hematogenous route.
Development of strategies to prevent or treat indwelling medical
device biofilm infections relies heavily on the availability of
relevant in vivo models amenable to preclinical trial evaluation
[6,10,11,38,41,42]. Our results demonstrated that our model of
TIVAP-related biofilm infections might be a valuable tool for
assessing therapeutic strategies against device-related biofilm
infection. In this study, we evaluated the efficiency of the antibiotic
lock therapy (ALT), a widely used strategy recommended in case
of uncomplicated catheter-related bloodstream infection (CRBSI)
caused by coagulase-negative staphylococci and Gram-negative
bacteria [43,44,45]. In the case of S. aureus CRBSI, treatment
failure and hematogenous complications are frequent [44,46]. We
therefore focused on this difficult-to-treat pathogen and showed
that clinically proposed high concentrations of gentamicin or
cefazolin alone did not eradicate S. aureus biofilm, as indicated by
the persistence of luminescent signals and high CFU counts in
TIVAP after treatment. However, combined antibiotics acted
synergistically and led to clearance of the dense biofilms formed in
TIVAP within 72 h of treatment. While this clearly illustrates the
high tolerance of biofilms towards antibiotics, it also suggested that
our model could be used to assess the curative or preventive
efficiency of innovative combinatorial ALT solutions or antibac-
terial/anti-adhesive impregnated catheters. In addition to new
antibiofilm approaches, our model permits evaluation of other
aspects of clinical handling of TIVAP, including recolonization
after replacement of contaminated TIVAP, flush protocols and
antithrombotic monitoring.
In conclusion, we describe a new in vivo model that would
contribute to a better understanding of device-related infections by
addressing numerous clinically relevant issues, including the
impact of the immune system on the kinetic of establishment
and control of biofilm-related infections. This model will also allow
assessment of diagnostic or therapeutic anti-biofilm and throm-
bosis approaches, as well as optimization of long-term manage-
ment of implanted medical devices.
Supporting Information
Figure S1 Increase in bacterial count is correlated with
increased luminescence and CFU. Bacteria were grown in
liquid medium (LB for E. coli and P. aeruginosa and TSB glucose for
S. aureus and S. epidermidis) and samples were harvested over time to
evaluate bacterial concentration (–N–, CFU/mL) and relative
bioluminescence (–%–, ROI, p/S/cm
2/sr). (A–C) For E. coli, P.
aeruginosa and S. aureus bioluminescence followed growth and
remained relatively high. (D) S. epidermidis showed a marked
decrease in bioluminescence over time with increasing CFU and
displayed lower levels of bioluminescence than the other bacteria.
All the values are mean +/2 standard deviation of 3 values.
(TIF)
Figure S2 Surgical implantation of TIVAP in rats.
TIVAP were surgically implanted in CD/SD (IGS: Crl)
rats. (A) Surgery was performed under laminar air flow and
aseptic conditions were maintained throughout the surgical
procedure. (B) Rats were briefly kept in an isoflurane chamber
to calm down and injected intraperitoneally with a ketamine/
xylazine/acepromazine mixture to complete sedation and analge-
sia before starting the procedure. (C) After shaving and skin
disinfection, an incision was made at the dorsal midline. (D) The
catheter from the pediatric TIVAP was cut at a 10/11 cm length.
(E). A subcutaneous pocket was created and the port carefully
inserted before being held intact by sutures (F). (G) An incision was
made in the neck area on the ventral side and a Huber needle
connected to a tuberculin syringe was inserted into the port. (H)
The catheter was tunneled under the skin with the help of a
tunneling rod provided with the TIVAP kit. (I) The external
jugular vein was exposed and two cotton threads inserted beneath
the vein on the proximal and distal sides. The catheter was cut at a
slant. (J) A small incision was made in the jugular vein and the
sacrificed after 120 h of treatment and analyzed. (A) 5 mg/mL cefazolin ALT. (B) 1 mg/mL gentamicin ALT. (C) Combined cefazolin and gentamicin
ALT (1:1 v/v). (D–E) TIVAP were aseptically removed and photon emission due to remnant biofilm measured. (D) Cefazolin-treated TIVAP, (E)
gentamicin-treated TIVAP and (F) TIVAP treated with cefazolin and gentamicin combination. In (A) to (F) representative experiments are shown. (G)
TIVAP was extracted after treatment and cells were harvested and plated for CFU/mL. All the values are mean +/2 standard deviation. Statistical
analysis was done using one-way analysis of variance (ANOVA) using Graphpad Prism version 5.0c. p value,0.05 considered significant, ***
(p,0.0001), ** (p,0.001) and * (p,0.05).
doi:10.1371/journal.pone.0037281.g006
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cava. (K) Blood reflux was checked by pulling the blood carefully
and the TIVAP was flushed with 1X PBS. The catheter was held
in place by tying the threads. Suturing of both the dorsal and
ventral sides closed the wounds (L) and (M). Lidocaine and
betadine were applied to the wounds and rats were allowed to
recover for 4 days prior to inoculation. Surgical wounds healed
within a week (N) and (O).
(TIF)
Figure S3 Long-term biofilms formed in TIVAP im-
planted in rats. Several rats (n=3, for each strain) with
implanted TIVAP were monitored for persistent infection over a
long period of time. Persistent biofilm growth was observed for E.
coli up to 60 days (A), for P. aeruginosa up to 65 days (B) and for S.
aureus up to a period of 128 days (C). (D) Rats were sacrificed and
TIVAP removed to confirm the presence of biofilms by
luminescence.
(TIF)
Figure S4 Mimicking of hematogenous colonization.
Central venous catheters were colonized by bacteria from other
infection routes, including bloodstream infection. (A) 5610
8 CFU/
500 mL 1X PBS were injected through the tail vein of TIVAP-
implanted rats (n=6). Photon emission due to bacterial coloniza-
tion on the TIVAP was monitored and appeared to localize at the
catheter tip. (B) Localization of bacterial biofilm on the tip of the
TIVAP (n=2/6) was confirmed by removal on day 3 post
intravenous injection and imaging of the catheter. Approximately
10
4 CFU were detected after resuspension of 1 cm of the catheter
tip. Representative images are presented.
(TIF)
Figure S5 Immunosuppression led to fatal biofilm
borne infection due to bacteremia and severe organ
infection. (A) TIVAP was surgically removed and cells harvested
from the catheter (Cath) and port separately and plated for CFU/
mL. Data are presented as box-and-whisker plots as previously
described in Material and Methods. (B) Peripheral blood was
withdrawn by puncturing the retro-orbital sinus on the final day of
the experiment and plated for CFU/mL. (C) Organs were
aseptically removed on the last day of the experiment, homoge-
nized and plated for CFU/mL. All organs were heavily
contaminated (all four pathogenic bacteria) with up to 10
9
CFU/mL. CFU were estimated on LB agar (E.c., E. coli) or P.a.,
P. aeruginosa) or TSB agar (S.a., S. aureus or S.e., S. epidermidis) plates.
Data are presented as box-and-whisker plots as previously
described. Number of rats (n) used in the experiment, n=4 for
each strain.
(TIF)
Figure S6 Exacerbation of immune cells in peripheral
blood in systemically infected rats. Blood was collected
from the rats by retro-orbital puncture as described in material
and methods and analysed using ABC vet automated blood
analysis machine. (A) Total leukocyte count for control (uninfected
rats, n=6), E. coli (n=3), P. aeruginosa (healthy, n=5; sick, n=4)
and S. aureus (healthy, n=3 and sick n=3). (B) Granulocyte count
in peripheral blood for control (uninfected rats, n=6), E. coli
(n=3), P. aeruginosa (healthy, n=5; sick, n=4) and S. aureus
(healthy, n=3 and sick n=3). Statistical analysis was done using
one-way analysis of variance (ANOVA) using Graphpad Prism
version 5.0c. Except when indicated by connectors statistical
comparisons were made with control. p value,0.05 considered
significant, *** (p,0.0001), ** (p,0.001) and * (p,0.05).
(TIF)
Figure S7 ALT treatment of S. aureus biofilms can lead
to systemic infection in animals. Treatment of biofilm
colonization in TIVAP-implanted rats with ALT led to systemic
infection when not combined with systemic treatment. (A) ALT
(0 h) was instilled on day 4 post-biofilm colonization in TIVAP.
ALT treatment led to flushing of bacteria into the bloodstream for
30% of treated rats and led to organ infection (n=3/9). (B) Rat
showing systemic infection after 168 h of ALT treatment leading
to its death. TIVAP was removed and luminescence measured,
confirming persistent biofilm colonization. A representative
experiment is shown.
(TIF)
Table S1 Microbiological analysis of TIVAP removed
from human patients (n=279) with suspected catheter-
related infection.
(DOCX)
Table S2 In vivo relation between ROI (p/s/cm
2/sr)
and CFU/ml in port of implanted TIVAP at 10 dpi.
(DOCX)
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